Evidence map›Paper›PMID 41116087›Full record

ArticleFunctional & integrative genomics2025

CRLS1 influences liver metastasis in colon cancer by regulating lipid metabolism pathways.

Junbo Mu, Donghao Li, Honglei Shen, Mengyuan Cao, Luye Zhang, Cangxue Wang, Keni Sun, Han Wang, Yiyang He, Kejun Liu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Junbo MuGuangxi Medical University Cancer Hospital, Qingxiu District, Nanning, Guangxi, China.
Donghao LiSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Honglei ShenGuangxi Medical University Cancer Hospital, Qingxiu District, Nanning, Guangxi, China.
Mengyuan CaoHenan Medicine College, Zhengzhou University, Zhengzhou, Henan, China.
Luye ZhangHenan Medicine College, Zhengzhou University, Zhengzhou, Henan, China.
Cangxue WangSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Keni SunHenan Medicine College, Zhengzhou University, Zhengzhou, Henan, China.
Han WangHenan Medicine College, Zhengzhou University, Zhengzhou, Henan, China.
Yiyang HeHenan Medicine College, Zhengzhou University, Zhengzhou, Henan, China.
Kejun LiuHenan Medicine College, Zhengzhou University, Zhengzhou, Henan, China.
Xin HuangSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Quankun LiangGuangxi Medical University Cancer Hospital, Qingxiu District, Nanning, Guangxi, China.
Weizhong TangGuangxi Medical University Cancer Hospital, Qingxiu District, Nanning, Guangxi, China. tangweizhong@gxmu.edu.cn.
Xuhui KongSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China. kongxh@zzu.edu.cn.

Funding

the China Postdoctoral Science Foundation 2024M763002the National Natural Science Foundation of China 32500757
6 · The paper itself

Abstract

Colon cancer is one of the leading causes of cancer-related mortality, with liver metastasis commonly complicating its progression and significantly worsening patient prognosis. This study aims to explore the relationship between liver metastasis in colon cancer and various clinicopathological factors, as well as to investigate the underlying molecular mechanisms. The clinical data and weighted gene co-expression network analysis (WGCNA) were used to identify key genes associated with liver metastasis. The results revealed significant alterations in lipid metabolism associated with colon cancer progression. Notably, WGCNA and machine learning algorithms identified cardiolipin synthase 1 (CRLS1) as a hub gene robustly associated with liver metastasis in colon cancer. The expression of CRLS1 was assessed via scRNA-seq and the collection of clinical samples from colon cancer patients. CRLS1 knockdown significantly inhibited the proliferation and migration of colon cancer cells and suppressed lipid metabolism. Finally, several candidate drugs have been identified that may effectively target CRLS1. Moreover, it has been confirmed that the mTOR signaling pathway regulates CRLS1 expression, offering a promising avenue for future therapeutic strategies. In conclusion, this study highlights the pivotal role of CRLS1 in colon cancer and its potential as a biomarker and therapeutic target through lipid metabolism in managing this aggressive disease.

Indexed as

Colonic NeoplasmsLipid MetabolismLiver NeoplasmsTransferases (Other Substituted Phosphate Groups)Cell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMaleSignal TransductionTOR Serine-Threonine KinasesMTOR protein, humanTOR Serine-Threonine KinasesTransferases (Other Substituted Phosphate Groups)BioinformaticsColon cancerCRLS1Lipid metabolismLiver metastasis

Identifiers

PMID41116087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.